Urinary Aquaporin 2 Excretion After Methylprednisolone in Fasting Healthy Humans

Condition(s) targeted: Healthy

Intervention: Methylprednisolone (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Holstebro Hospital

Official(s) and/or principal investigator(s):
Erling B Pedersen, Professor, Study Chair, Affiliation: Holstebro Hospital, 7500 Holstebro, Denmark
Thomas G Knudsen, MD, Principal Investigator, Affiliation: Holstebro Sygehus

We wanted to test the hypotheses that methylprednisolone up regulates u-AQP-2 in fasting healthy humans

Official title: Urinary Aquaporin 2 Excretion After Methylprednisolone in Fasting Healthy Humans

Study design: Randomized, Single Blind, Placebo Control, Crossover Assignment

Primary outcome:

u-AQP-2

FeNa+

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- (1) Genders; both mal and female

- (2) Age; 18- 65 years old

- (3) BMI; below 30

- (4) Females had to bee in oral contraceptive treatment

Exclusion Criteria:

- (1) Clinical signs or history of disease in the heart, lungs, kidneys or endocrine

organs

- (2) Abnormal laboratory test (blood haemoglobin, white cell count, platelets, plasma

sodium, plasma potassium, plasma creatinine, plasma albumin, plasma bilirubin, plasma alanine aminotransferase, plasma cholesterol and blood glucose)

- (3) Albuminuria or glucosuria

- (4) Cancer

- (5) Arterial hypertension

- (6) Alcohol abuse

- (7) Use of tobacco

- (8) Medical treatment, except oral contraceptives

- (9) Pregnancy or breast feeding

- (10) Medicine abuse

- (11) Donation of blood less than 1 month before the study.

Department of Medicine, Holstebro Hospital, Holstebro, Denmark

Starting date: October 2005
Ending date: February 2007
Last updated: May 6, 2008